Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

NCT04084444 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Abnormal Immune Activation in HIV/AIDS

Interventions

DRUG: T8 tablet 0.5mg
DRUG: T8 tablet 1mg
DRUG: Placebo

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd